ArticleTranslational vision science & technology2020
Dupilumab-Associated Mucin Deficiency (DAMD).
Article in Translational vision science & technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- Diet-Microbiome-Immune Interactions at the Gut Mucosa in Food Allergy: Mechanisms, Gaps, and Therapeutic Implications.Allergy · 2026Review
- Long-Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry.Clinical and translational allergy · 2026Article
- Early Ocular-Surface Changes During Dupilumab Treatment According to Hyaluronic Acid Use: A Prospective Cohort Study.Journal of personalized medicine · 2026Article
- Clinical characteristics and management of dupilumab-associated ocular surface disease in Japan.Japanese journal of ophthalmology · 2026Review
- Dupilumab-Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Article
- Ocular Side Effects of Dupilumab: A Comprehensive Overview of the Literature.Journal of clinical medicine · 2025Review
- Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease.Journal of ophthalmic inflammation and infection · 2024Article
- Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Pharmaceutics · 2023Article
- Differential nasal swab cytology represents a valuable tool for therapy monitoring but not prediction of therapy response in chronic rhinosinusitis with nasal polyps treated with Dupilumab.Frontiers in immunology · 2023Article
- Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.Frontiers in medicine · 2023Review
- IL-4 and IL-13 both contribute to the homeostasis of human conjunctival goblet cells in vitro.Allergy · 2022Article
- Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases.Clinical reviews in allergy & immunology · 2022Review
- Ocular surface disease is common in moderate-to-severe atopic dermatitis patients.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Article
- A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2021Review
- Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease.International journal of molecular sciences · 2021Review
- Dupilumab Induced Limbal Stem Cell Deficiency.International medical case reports journal · 2021Article
- Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis.American journal of ophthalmology case reports · 2020Article
- Restoring the mucin barrier: Advances in secretagogue therapies for ocular surface disorders.Taiwan journal of ophthalmologyReview
- Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab-Associated Conjunctivitis in Patients with Atopic Dermatitis.Ophthalmology scienceArticle
Corrections and comments
- Erratum issuedErratum.2020
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Purpose: Dupilumab, a monoclonal antibody directed against the interleukin-4 receptor subunit α (IL-4Rα) of IL-4 and IL-13, is increasingly being used to control atopic disease. Dupilumab use has been associated with a poorly understood conjunctivitis. In this study, we sought to investigate the hypothesis that dupilumab use and the associated IL-13 blockade causes a relative ocular mucin deficiency. Methods: Tear levels of mucin 5ac (Muc5AC) and total tear protein levels were evaluated from 28 eyes of 14 patients. Bilateral tear samples were acquired from seven patients on dupilumab and seven patients with no exposure to dupilumab. Study subjects were age and gender matched. In addition to tear samples, photographic documentation of ocular surface findings and a questionnaire of ocular surface symptoms were obtained. Between-group mean differences were calculated. Results: Compared with control, ocular Muc5AC levels normalized to total tear protein was statistically significantly lower. The average Muc5AC levels for persons on dupilumab was 1.54 ± 0.58 ng/mg and that of controls was 7.99 ± 1.16 ng/ mg. Persons on dupilumab reported a statistically increased occurrence of ocular fatigue/eye strain, uncomfortable sensation, pain, red eye, and itching. Conclusions: This study demonstrates for the first time, a relative deficiency of Muc5AC in patients on dupilumab. Translational Relevance: The results of this study support the previously reported role of IL-13 in increasing goblet cell density and associated Muc5AC production. Further efforts are underway to better understand the relative contribution of Muc5AC deficiency in the overall presentation of conjunctivitis associated with dupilumab use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.